Primary Sjögren's Syndrome
6
Pipeline Programs
5
Companies
6
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
5
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
5 companies ranked by most advanced pipeline stage
argenxBelgium - Zwijnaarde
2 programs2
EfgartigimodPhase 21 trial
EfgartigimodPhase 21 trial
Active Trials
UP
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
ImmunovantIMVT-1402
argenxEfgartigimod
argenxEfgartigimod
UCB PharmaUCB5857
BiogenBaminercept
NovartisVAY736 lower dose
Clinical Trials (6)
Total enrollment: 137 patients across 6 trials
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
Start: Jun 2025Est. completion: Jul 2028
Phase 2Recruiting
Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome
Start: Nov 2023Est. completion: Feb 202524 patients
Phase 2Completed
A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS)
Start: Apr 2023Est. completion: Feb 202434 patients
Phase 2Completed
UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome
Start: Oct 2015Est. completion: Dec 201727 patients
Phase 2Terminated
Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome
Start: Jul 2012Est. completion: Jun 201552 patients
Phase 2Terminated
Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome
Start: Dec 2015Est. completion: Sep 20170
Phase 1/2Withdrawn
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 137 patients
5 companies competing in this space